179 related articles for article (PubMed ID: 35587181)
1. Methods for Communicating the Impact of Parameter Uncertainty in a Multiple-Strategies Cost-Effectiveness Comparison.
Wolff HB; Qendri V; Kunst N; Alarid-Escudero F; Coupé VMH
Med Decis Making; 2022 Oct; 42(7):956-968. PubMed ID: 35587181
[TBL] [Abstract][Full Text] [Related]
2. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).
Barton GR; Briggs AH; Fenwick EA
Value Health; 2008; 11(5):886-97. PubMed ID: 18489513
[TBL] [Abstract][Full Text] [Related]
3. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
4. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis.
Groot Koerkamp B; Hunink MG; Stijnen T; Hammitt JK; Kuntz KM; Weinstein MC
Med Decis Making; 2007; 27(2):101-11. PubMed ID: 17409361
[TBL] [Abstract][Full Text] [Related]
5. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation.
Fenwick E; Marshall DA; Levy AR; Nichol G
BMC Health Serv Res; 2006 Apr; 6():52. PubMed ID: 16623946
[TBL] [Abstract][Full Text] [Related]
6. Handling Uncertainty in Cost-Effectiveness Analysis: Budget Impact and Risk Aversion.
Sendi P; Matter-Walstra K; Schwenkglenks M
Healthcare (Basel); 2021 Oct; 9(11):. PubMed ID: 34828466
[TBL] [Abstract][Full Text] [Related]
7. Presenting evidence and summary measures to best inform societal decisions when comparing multiple strategies.
Eckermann S; Willan AR
Pharmacoeconomics; 2011 Jul; 29(7):563-77. PubMed ID: 21671686
[TBL] [Abstract][Full Text] [Related]
8. Calibrating models in economic evaluation: a comparison of alternative measures of goodness of fit, parameter search strategies and convergence criteria.
Karnon J; Vanni T
Pharmacoeconomics; 2011 Jan; 29(1):51-62. PubMed ID: 21142278
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness acceptability curves revisited.
Al MJ
Pharmacoeconomics; 2013 Feb; 31(2):93-100. PubMed ID: 23329426
[TBL] [Abstract][Full Text] [Related]
10. Beyond the cost-effectiveness acceptability curve: The appropriateness of rank probabilities for presenting the results of economic evaluation in multiple technology appraisal.
Epstein D
Health Econ; 2019 Jun; 28(6):801-807. PubMed ID: 31050043
[TBL] [Abstract][Full Text] [Related]
11. A cost-effectiveness analysis of freeze-only or fresh embryo transfer in IVF of non-PCOS women.
Le KD; Vuong LN; Ho TM; Dang VQ; Pham TD; Pham CT; Norman RJ; Mol BWJ
Hum Reprod; 2018 Oct; 33(10):1907-1914. PubMed ID: 30239784
[TBL] [Abstract][Full Text] [Related]
12. Generating, Presenting, and Interpreting Cost-Effectiveness Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better Practice.
Bilcke J; Beutels P
Med Decis Making; 2022 May; 42(4):421-435. PubMed ID: 34651515
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of alternative strategies for the initial medical management of non-ST elevation acute coronary syndrome: systematic review and decision-analytical modelling.
Robinson M; Palmer S; Sculpher M; Philips Z; Ginnelly L; Bowens A; Golder S; Alfakih K; Bakhai A; Packham C; Cooper N; Abrams K; Eastwood A; Pearman A; Flather M; Gray D; Hall A
Health Technol Assess; 2005 Jul; 9(27):iii-iv, ix-xi, 1-158. PubMed ID: 16022802
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
15. The augmented representation of the cost-effectiveness acceptability curve for economic evaluation of health technology.
Araki D; Kamae I
Kobe J Med Sci; 2015 Mar; 61(1):E9-18. PubMed ID: 25868612
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity Analysis in Sequential Decision Models.
Chen Q; Ayer T; Chhatwal J
Med Decis Making; 2017 Feb; 37(2):243-252. PubMed ID: 27681992
[TBL] [Abstract][Full Text] [Related]
17. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
18. Real-World Cost-Effectiveness Analysis: How Much Uncertainty Is in the Results?
Barr HK; Guggenbickler AM; Hoch JS; Dewa CS
Curr Oncol; 2023 Apr; 30(4):4078-4093. PubMed ID: 37185423
[TBL] [Abstract][Full Text] [Related]
19. Better informing decision making with multiple outcomes cost-effectiveness analysis under uncertainty in cost-disutility space.
McCaffrey N; Agar M; Harlum J; Karnon J; Currow D; Eckermann S
PLoS One; 2015; 10(3):e0115544. PubMed ID: 25751629
[TBL] [Abstract][Full Text] [Related]
20. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
